✦ LIBER ✦

Re: Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer

✍ Scribed by Taneja, Samir S.

Book ID: 123541729
Publisher: Lippincott Williams and Wilkins
Year: 2012
Tongue: English
Weight: 98 KB
Volume: 188
Category: Article
ISSN: 0022-5347
DOI: 10.1016/j.juro.2012.08.169

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and Activity of Anti–PD-L1 Antibo

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

✍ Brahmer, Julie R.; Tykodi, Scott S.; Chow, Laura Q.M.; Hwu, Wen-Jen; Topalian, S 📂 Article 📅 2012 🏛 Massachusetts Medical Society 🌐 English ⚖ 627 KB

Safety, Activity, and Immune Correlates

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

✍ Topalian, Suzanne L.; Hodi, F. Stephen; Brahmer, Julie R.; Gettinger, Scott N.; 📂 Article 📅 2012 🏛 Massachusetts Medical Society 🌐 English ⚖ 684 KB

Safety and activity of Capecitabine in e

Safety and activity of Capecitabine in elderly patients with advanced breast cancer

✍ G. Procopio; E. Bajetta; L. Catena; M. Alù; R. Longarini; N. Zilembo; I. La Torr 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 195 KB

Phase I Study of the Anti-MUC-l Antibody

Phase I Study of the Anti-MUC-l Antibody, huHMFG1 (AS1402), in Patients with Advanced Breast Cancer

✍ Nigel Courtenay-Luck; Mark Pegram 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Phase I safety, pharmacokinetic and phar

Phase I safety, pharmacokinetic and pharmacodynamic study of recombinant human anti-VEGF antibody HuMV833 in patients with advanced cancer

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 140 KB

Safety, pharmacokinetics and pharmacodyn

Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer

✍ Infante, Jeffrey R.; Bendell, Johanna C.; Goff, Laura Williams; Jones, Suzanne F 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 511 KB